BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487-496. [PMID: 24950263 DOI: 10.1097/sla.0000000000000757] [Cited by in Crossref: 107] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Papamichael K, Cheifetz AS. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis 2016;10:507-9. [PMID: 26874348 DOI: 10.1093/ecco-jcc/jjw041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
2 Lowenfeld L, Cologne KG. Postoperative Considerations in Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1095-109. [PMID: 31676050 DOI: 10.1016/j.suc.2019.08.003] [Reference Citation Analysis]
3 Quaresma AB, Yamamoto T, Kotze PG. Biologics and surgical outcomes in Crohn's disease: is there a direct relationship? Therap Adv Gastroenterol 2020;13:1756284820931738. [PMID: 32728389 DOI: 10.1177/1756284820931738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
4 Fleshner P, Melmed GY. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. Clin Colon Rectal Surg 2022;35:066-71. [DOI: 10.1055/s-0041-1740030] [Reference Citation Analysis]
5 Liu W, Zhou W. Surgery for inflammatory bowel disease in the era of biologics. Shijie Huaren Xiaohua Zazhi 2021; 29(22): 1311-1315 [DOI: 10.11569/wcjd.v29.i22.1311] [Reference Citation Analysis]
6 Cai X, Shen W, Guo Z, Li Y, Cao L, Gong J, Zhu W. Thickness of Subcutaneous Fat Is a Predictive Factor of Incisional Surgical Site Infection in Crohn's Disease Surgery: A Retrospective Study. Gastroenterol Res Pract 2018;2018:1546075. [PMID: 30140279 DOI: 10.1155/2018/1546075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 . The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes In Inflammatory Bowel Disease Surgery: Erratum. Ann Surg 2018;267:e62. [PMID: 29401134 DOI: 10.1097/SLA.0000000000002544] [Reference Citation Analysis]
8 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
9 Baker JF, George MD. Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression. Curr Rheumatol Rep 2019;21:17. [PMID: 30847768 DOI: 10.1007/s11926-019-0812-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Levartovsky A, Ben-Horin S. Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe? J Crohns Colitis 2021:jjab167. [PMID: 34626174 DOI: 10.1093/ecco-jcc/jjab167] [Reference Citation Analysis]
11 Alsaleh A, Gaidos JK, Kang L, Kuemmerle JF. Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients. Dig Dis Sci 2016;61:2602-7. [PMID: 27126205 DOI: 10.1007/s10620-016-4171-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Guyton K, Kearney D, Holubar SD. Anastomotic Leak after Ileal Pouch-Anal Anastomosis. Clin Colon Rectal Surg 2021;34:417-25. [PMID: 34853564 DOI: 10.1055/s-0041-1735274] [Reference Citation Analysis]
13 Ward MM, Dasgupta A. Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology (Oxford) 2020;59:3917-26. [PMID: 32710102 DOI: 10.1093/rheumatology/keaa291] [Reference Citation Analysis]
14 El-hussuna A, Myrelid P, Holubar SD, Kotze PG, Mackenzie G, Pellino G, Winter D, Davies J, Negoi I, Grewal P, Gallo G, Sahnan K, Rubio-perez I, Clerc D, Demartines N, Glasbey J, Regueiro M, Sherif AE, Neary P, Pata F, Silverberg M, Clermont S, Chadi SA, Emile S, Buchs N, Millan M, Minaya-bravo A, Elfeki H, De Simone V, Shalaby M, Gutierrez C, Ozen C, Yalçınkaya A, Rivadeneira D, Sturiale A, Yassin N, Spinelli A, Warusavitarne J, Ioannidis A, Wexner S, Mayol J; Open Source Research Collaborating Group (#OpenSourceResearch). Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. Crohn's & Colitis 360 2019;1:otz021. [DOI: 10.1093/crocol/otz021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Soop M, Khan H, Nixon E, Teubner A, Abraham A, Carlson G, Lal S. Causes and Prognosis of Intestinal Failure in Crohn's Disease: An 18-year Experience From a National Centre. J Crohns Colitis. 2020;14:1558-1564. [PMID: 32215559 DOI: 10.1093/ecco-jcc/jjaa060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yamamoto T, Spinelli A, Suzuki Y, Saad-Hossne R, Teixeira FV, de Albuquerque IC, da Silva RN, de Barcelos IF, Takeuchi K, Yamada A, Shimoyama T, da Silva Kotze LM, Sacchi M, Danese S, Kotze PG. Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United European Gastroenterol J 2016;4:784-93. [PMID: 28408996 DOI: 10.1177/2050640615600116] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
17 García MJ, Rivero M, Miranda-Bautista J, Bastón-Rey I, Mesonero F, Leo-Carnerero E, Casas-Deza D, Cagigas Fernández C, Martin-Cardona A, El Hajra I, Hernández-Aretxabaleta N, Pérez-Martínez I, Fuentes-Valenzuela E, Jiménez N, Rubín de Célix C, Gutiérrez A, Suárez Ferrer C, Huguet JM, Fernández-Clotet A, González-Vivó M, Del Val B, Castro-Poceiro J, Melcarne L, Dueñas C, Izquierdo M, Monfort D, Bouhmidi A, Ramírez De la Piscina P, Romero E, Molina G, Zorrilla J, Calvino-Suárez C, Sánchez E, Nuñez A, Sierra O, Castro B, Zabana Y, González-Partida I, De la Maza S, Castaño A, Nájera-Muñoz R, Sánchez-Guillén L, Riat Castro M, Rueda JL, Benítez JM, Delgado-Guillena P, Tardillo C, Peña E, Frago-Larramona S, Rodríguez-Grau MC, Plaza R, Pérez-Galindo P, Martínez-Cadilla J, Menchén L, Barreiro-De Acosta M, Sánchez-Aldehuelo R, De la Cruz MD, Lamuela LJ, Marín I, Nieto-García L, López-San Román A, Herrera JM, Chaparro M, Gisbert JP, On Behalf Of The Young Group Of Geteccu. Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. J Clin Med 2021;10:4402. [PMID: 34640421 DOI: 10.3390/jcm10194402] [Reference Citation Analysis]
18 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
19 Di Candido F, Moggia E, Spinelli A. Pre-operative optimisation in Crohn's Disease. Seminars in Colon and Rectal Surgery 2020;31:100742. [DOI: 10.1016/j.scrs.2020.100742] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Qiu Y, Zheng Z, Liu G, Zhao X, He A. Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. United European Gastroenterol J 2019;7:1198-214. [PMID: 31700633 DOI: 10.1177/2050640619878998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Byrne LW, McKay D. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review. Surgeon 2021;19:e153-67. [PMID: 34581275 DOI: 10.1016/j.surge.2020.09.001] [Reference Citation Analysis]
22 Gaines S, Hyoju S, Williamson AJ, van Praagh JB, Zaborina O, Rubin DT, Alverdy JC, Shogan BD, Hyman N. Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis. J Gastrointest Surg 2020;24:2637-42. [PMID: 31898107 DOI: 10.1007/s11605-019-04486-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
24 Ikeshima R, Mizushima T, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Nakajima K, Yamamoto H, Murata K, Doki Y, Mori M. The efficacy of active drainage for preventing postoperative organ/space surgical site infections in patients with Crohn's disease. Surg Today 2018;48:25-32. [PMID: 28608250 DOI: 10.1007/s00595-017-1549-z] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Reindl W, Thomann AK, Galata C, Kienle P. Reducing Perioperative Risks of Surgery in Crohn's Disease. Visc Med 2019;35:348-54. [PMID: 31934582 DOI: 10.1159/000504030] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 George MD, Baker JF. Perioperative management of immunosuppression in patients with rheumatoid arthritis. Curr Opin Rheumatol 2019;31:300-6. [PMID: 30920454 DOI: 10.1097/BOR.0000000000000589] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 von Allmen D. Pediatric Crohn's Disease. Clin Colon Rectal Surg 2018;31:80-8. [PMID: 29487490 DOI: 10.1055/s-0037-1609022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper. Inflamm Bowel Dis 2015;21:2658-72. [PMID: 26422516 DOI: 10.1097/MIB.0000000000000603] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
29 Shwaartz C, Fields AC, Sobrero M, Cohen BD, Divino CM. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience. J Gastrointest Surg 2016;20:1636-42. [DOI: 10.1007/s11605-016-3194-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
30 Kamperidis N, Faiz O, Arebi N. The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery. Ann Surg 2017;266:e61-2. [PMID: 29136975 DOI: 10.1097/SLA.0000000000001502] [Reference Citation Analysis]
31 Huang Y, Yao D, Guo F, Zhou Z, Li Y. Preoperative Anti-TNF Therapy is Associated with a Shorter Length of Resected Bowel in Patients Undergoing Ileocolic Resection for Crohn's Disease. J Invest Surg 2022;:1-9. [PMID: 34983280 DOI: 10.1080/08941939.2021.2023713] [Reference Citation Analysis]
32 Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, Martinez CA, Ayrizono ML, Magro DO, Coy CS. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. Dig Dis Sci 2017;62:456-64. [PMID: 27933472 DOI: 10.1007/s10620-016-4400-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
33 Hanzel J, Almradi A, Istl AC, Yang ML, Fleshner KA, Parker CE, Guizzetti L, Ma C, Singh S, Jairath V. Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. Dig Dis Sci 2021. [PMID: 33634430 DOI: 10.1007/s10620-021-06895-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Galata C, Weiss C, Hardt J, Seyfried S, Post S, Kienle P, Horisberger K. Risk factors for early postoperative complications and length of hospital stay in ileocecal resection and right hemicolectomy for Crohn's disease: a single-center experience. Int J Colorectal Dis 2018;33:937-45. [PMID: 29736773 DOI: 10.1007/s00384-018-3072-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
35 El-Hussuna A, Qvist N, Zangenberg MS, Langkilde A, Siersma V, Hjort S, Gögenur I. No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study. BMC Surg 2018;18:91. [PMID: 30390672 DOI: 10.1186/s12893-018-0425-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
36 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
37 Fumery M, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet JM, Boschetti G, Cotte E, Buisson A, Dubois A, Pariente B, Zerbib P, Chafai N, Stefanescu C, Panis Y, Marteau P, Pautrat K, Sabbagh C, Filippi J, Chevrier M, Houze P, Jouven X, Treton X, Allez M;  REMIND study group investigators. Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. Am J Gastroenterol. 2017;112:337-345. [PMID: 27958285 DOI: 10.1038/ajg.2016.541] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
38 Kulaylat AS, Kulaylat AN, Schaefer EW, Tinsley A, Williams E, Koltun W, Hollenbeak CS, Messaris E. Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis. JAMA Surg 2017;152:e171538. [PMID: 28614561 DOI: 10.1001/jamasurg.2017.1538] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
39 Quaresma AB, Baraúna FDSB, Teixeira FV, Saad-Hossne R, Kotze PG. Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review. J Clin Med 2021;10:710. [PMID: 33670200 DOI: 10.3390/jcm10040710] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Luo WY, Singh S, Cuomo R, Eisenstein S. Modified two-stage restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis of observational research. Int J Colorectal Dis 2020;35:1817-30. [PMID: 32715346 DOI: 10.1007/s00384-020-03696-7] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kotze PG, Ma C, Mckenna N, Almutairdi A, Kaplan GG, Raffals LE, Loftus EV Jr, Panaccione R, Lightner AL. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Therap Adv Gastroenterol 2018;11:1756284818783614. [PMID: 29977340 DOI: 10.1177/1756284818783614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Masaki T, Kishiki T, Kojima K, Asou N, Beniya A, Matsuoka H. Recent trends (2016-2017) in the treatment of inflammatory bowel disease. Ann Gastroenterol Surg 2018;2:282-8. [PMID: 30003191 DOI: 10.1002/ags3.12177] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
43 Ogino T, Mizushima T, Matsuda C, Mori M, Doki Y. Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases. Ann Gastroenterol Surg 2020;4:30-8. [PMID: 32021956 DOI: 10.1002/ags3.12304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
44 Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med 2021;10:5642. [PMID: 34884344 DOI: 10.3390/jcm10235642] [Reference Citation Analysis]
45 Kotze PG, Ghosh S, Bemelman WA, Panaccione R. Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. Intest Res 2017;15:160-5. [PMID: 28522944 DOI: 10.5217/ir.2017.15.2.160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
46 Heriot A, Smart P. Current Status of Segmental Colectomy in Select Crohn's Disease Patients. Clin Colon Rectal Surg 2019;32:249-54. [PMID: 31275070 DOI: 10.1055/s-0039-1683906] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
47 Aksan A, Farrag K, Blumenstein I, Schröder O, Dignass AU, Stein J. Chronic intestinal failure and short bowel syndrome in Crohn’s disease. World J Gastroenterol 2021; 27(24): 3440-3465 [PMID: 34239262 DOI: 10.3748/wjg.v27.i24.3440] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Garg R, Mohan BP, Ponnada S, Regueiro M, Lightner AL, Click B. Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn's disease: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:691-8. [PMID: 34475740 DOI: 10.20524/aog.2021.0634] [Reference Citation Analysis]
49 Kienle P. Impact of Modern Drug Therapy on Surgery: Crohn's Disease. Visc Med 2018;34:422-5. [PMID: 30675486 DOI: 10.1159/000495127] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Zangenberg MS, Horesh N, Kopylov U, El-Hussuna A. Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review. Int J Colorectal Dis. 2017;32:1663-1676. [PMID: 29051981 DOI: 10.1007/s00384-017-2915-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]